Celcuity logo

Celcuity

CELC | NASDAQ
Chart Builder DCF Calculator
$60.57
-$3.80 (-5.90%)
At close: Nov 16, 2026, 4:00 PM ET
$60.57
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:41 PM ET
-5.90%

Rating

Updated: Nov 16, 2026
22.6
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #972/1021 (Top 95%)

Key Statistics

Market Data

Market Cap $3.34B
1D Range
60.40 64.87
52W Range
56.58 144.98

Valuation (TTM)

PE -12.89
PB -45.11
EV/EBITDA -15.94

Valuation (NTM)

Forward PE 3,281.90
Forward PEG -0.40
Price Target $160.00
Loading financial charts...

Profile

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients tre...

Sector Healthcare
Industry Biotechnology
Employees 155
IPO Date Sep 19, 2017
Fiscal Year January - December

Latest News

Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

8 days ago · globenewswire.com

Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript

8 days ago · seekingalpha.com

Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript
What Celcuity (CELC) Said on Its Q3 Earnings Call

11 days ago · marketbeat.com

What Celcuity (CELC) Said on Its Q3 Earnings Call
Celcuity To Participate in Upcoming Investor Conferences

14 days ago · globenewswire.com

Celcuity To Participate in Upcoming Investor Conferences
Celcuity: Stronger Clinical Evidence, Much Lower Valuation

18 days ago · seekingalpha.com

Celcuity: Stronger Clinical Evidence, Much Lower Valuation
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call

19 days ago · globenewswire.com

Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

24 days ago · globenewswire.com

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

25 days ago · globenewswire.com

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

1 month ago · globenewswire.com

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Celcuity Appoints David Gryska To Its Board Of Directors

2 months ago · globenewswire.com

Celcuity Appoints David Gryska To Its Board Of Directors

Earnings

Next Earnings
Mar 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$160.00
Upside
+164.16%
Buy (9)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.